Rx Africa (Ethiopia) P.L.C is a pharmaceutical company, formerly known as Sunshine Pharmaceutical, which owns and operates a pharmaceutical manufacturing facility in Addis Ababa, Ethiopia. The plant was established to manufacture AIDS/HIV, malaria, tuberculosis and other generic drugs in Ethiopia.
Rx Africa (Ethiopia) P.L.C is currently producing six generic products for distribution in Ethiopia, with plans to increase its product line by a minimum of 30 new generic medicines over the next six months for sale throughout Ethiopia and the rest of Africa.
The Strategic Business Plan is an initiative undertaken to draw a roadmap for Rx Africa's growth. The company has tremendous potential in the African pharmaceuticals, Middle East, and other global markets. Rx Africa plans to make the most of these potential markets through a strategic alliance with its present and potential investors.
The Strategic Business Plan is presented in two major parts, namely, the Strategic Plan and the Business Plan. The company background, purpose, and strategies are presented in the first part. Rx Africa has a two-pronged strategy as its major growth thrust. In other words, efficacious, quality, and affordable pharmaceutical drugs will be produced and sold using own production and imported drugs. This strategy will provide value to consumers and owners simultaneously. The second part comprises the business plan consisting of the investment required, marketing analysis, financial analysis, and organizational management.
